Swapna Panuganti
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$1.7MFederal grants as PI2 awards
0Patents grantedNone matched
13Papers362 citations
Federal awards and patents by year
AwardsPatents
2 awards · $1.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Dec 17, 2018 | NIH | STTR Phase II Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation | $544K | Cellerant Therapeutics, Inc. |
| 2018 | NIH | STTR Phase II Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation | $1.1M | Cellerant Therapeutics, Inc. with CHILDREN'S MERCY HOSP (KANSAS CITY, MO) |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#1,265
Awards as PI#1,252
Patents#273
Companies
- Cellerant Therapeutics, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.